Study data presented at the American Heart Association meeting and published in The Lancet showed serelaxin, a drug for acute heart failure, met one of two primary end points in improving dyspnea. The University of California, San Francisco, study also found a significant decrease in cardiovascular deaths and lead author Dr. John Teerlink said other positive findings included shorter ICU says.